Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.
It's been a busy week or two for GlaxoSmithKline ($GSK)--the company has extended its agreement with Agenus ($AGEN), submitted two vaccines for approval and created a joint venture.
Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...
Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The